Cytomx Therapeutics, INC Form 4 insider transactions

Alejandra Carvajal, Chief Legal Officer of CytomX Therapeutics, Inc., reported multiple transactions in common stock on August 3, 2026.

Charles S. Fuchs, a Director of CytomX Therapeutics, Inc., received 118,000 shares of common stock on July 24, 2026.

CFO Christopher Ogden sold 1,624 shares of CytomX Therapeutics to cover tax withholding obligations related to RSU vesting.

CytomX Therapeutics' Chief Medical Officer, Yu-Waye Chu, sold 21,279 shares of common stock to cover tax obligations related to RSU vesting.

CytomX Therapeutics CEO Sean A. McCarthy sold 118,969 shares of common stock to cover tax obligations related to RSU vesting.

CytomX Therapeutics' Chief Scientific Officer, Marcia Belvin, sold 31,492 shares of common stock to cover tax obligations related to RSU vesting.

CytomX Therapeutics' CFO, Christopher Ogden, sold 19,323 shares of common stock to cover tax withholding obligations related to RSU vesting.

CytomX Therapeutics' Chief Business Officer, Rachael Lester, received significant equity grants including restricted stock units, stock options, and performance stock units, aligning her incentives with long-term company performance.

CytomX Therapeutics' Chief Medical Officer, Yu-Waye Chu, reported the acquisition of 75,000 restricted stock units and 300,000 stock options.

CytomX Therapeutics' SVP and Chief Scientific Officer, Marcia Belvin, reported the acquisition of 60,000 restricted stock units and 250,000 stock options.

CytomX Therapeutics' CFO Christopher Ogden was granted 90,000 restricted stock units and 325,000 stock options, aligning his interests with shareholders.

CytomX Therapeutics CEO Sean A. McCarthy was granted 210,000 restricted stock units and 980,000 stock options on February 2, 2026.

CytomX Therapeutics CEO Sean A. McCarthy sold 101,793 shares of Class A Common Stock for $4.5377 per share as part of a pre-arranged 10b5-1 trading plan.

CytomX Therapeutics' Chief Business Officer, Rachael Lester, was granted 650,000 stock options with an exercise price of $3.74.

CytomX Therapeutics CEO Sean A. McCarthy received new equity awards totaling 855,000 shares, comprising stock options and performance stock units, tied to future vesting and clinical milestones.

CytomX Therapeutics' Chief Medical Officer, Yu-Waye Chu, received grants of 87,500 stock options and 43,750 performance stock units.

CytomX Therapeutics' Chief Financial Officer, Christopher Ogden, was granted 78,250 stock options and 39,150 performance stock units, aligning his incentives with future company performance and clinical milestones.

CytomX Therapeutics' SVP and Chief Scientific Officer, Marcia Belvin, received 36,300 stock options and 18,150 performance stock units.

CytomX Therapeutics' Chief Financial Officer, Christopher Ogden, reported the vesting of performance stock units and subsequent sales of common stock to cover tax obligations.

CytomX Therapeutics, Inc.'s Senior Vice President and Chief Scientific Officer, Marcia Belvin, reported the vesting of performance stock units and a subsequent sale of shares to cover tax obligations.

CytomX Therapeutics CEO Sean McCarthy reported the vesting of 150,000 performance stock units and a subsequent sale of 55,511 shares to cover tax obligations.

CytomX Therapeutics, Inc. Director Zhen Su has been granted 38,000 stock options with an exercise price of $2.82 per share, aligning executive incentives with shareholder value.

CytomX Therapeutics, Inc. Director Matthew P. Young was granted 38,000 stock options with an exercise price of $2.82, vesting fully by the earlier of June 11, 2026, or the 2026 Annual Meeting.

CytomX Therapeutics, Inc. director Mani Mohindru was granted 38,000 stock options with an exercise price of $2.82, vesting on the earlier of the first anniversary of the grant date or the 2026 Annual Meeting.

James R. Meyers, a Director at CytomX Therapeutics, Inc. (CTMX), was granted 38,000 stock options with an exercise price of $2.82, aligning his interests with shareholders.

CytomX Therapeutics, Inc. Director Elaine V. Jones acquired 38,000 stock options with an exercise price of $2.82, vesting on the earlier of the first anniversary of the grant date or the 2026 Annual Meeting.

CytomX Therapeutics, Inc. Director Halley E. Gilbert was granted 38,000 stock options with an exercise price of $2.82, vesting fully by the earlier of June 11, 2026, or the 2026 Annual Meeting.

CytomX Therapeutics, Inc. director Alan Ashworth was granted 38,000 stock options with an exercise price of $2.82, aligning his interests with shareholder value.

CytomX Therapeutics CEO Sean A. McCarthy sold 37,656 shares of common stock on March 18, 2025, to satisfy tax obligations related to vesting restricted stock units.

Christopher Ogden, CFO of CytomX Therapeutics, sold 8,551 shares of common stock on March 18, 2025, to cover tax obligations related to vesting restricted stock units.